- Home
- FURY vs INKT Comparison
FURY vs INKT Comparison
Compare FURY & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FURY
- INKT
- Stock Information
- Founded
- FURY 2008
- INKT 2017
- Country
- FURY Canada
- INKT United States
- Employees
- FURY N/A
- INKT N/A
- Industry
- FURY Precious Metals
- INKT Medicinal Chemicals and Botanical Products
- Sector
- FURY Basic Materials
- INKT Health Care
- Exchange
- FURY Nasdaq
- INKT Nasdaq
- Market Cap
- FURY 84.1M
- INKT 69.2M
- IPO Year
- FURY N/A
- INKT 2021
- Fundamental
- Price
- FURY $0.72
- INKT $14.73
- Analyst Decision
- FURY Strong Buy
- INKT Buy
- Analyst Count
- FURY 2
- INKT 3
- Target Price
- FURY $1.40
- INKT $37.50
- AVG Volume (30 Days)
- FURY 1.2M
- INKT 38.9K
- Earning Date
- FURY 11-11-2025
- INKT 11-13-2025
- Dividend Yield
- FURY N/A
- INKT N/A
- EPS Growth
- FURY N/A
- INKT N/A
- EPS
- FURY N/A
- INKT N/A
- Revenue
- FURY N/A
- INKT N/A
- Revenue This Year
- FURY N/A
- INKT N/A
- Revenue Next Year
- FURY N/A
- INKT N/A
- P/E Ratio
- FURY N/A
- INKT N/A
- Revenue Growth
- FURY N/A
- INKT N/A
- 52 Week Low
- FURY $0.35
- INKT $4.56
- 52 Week High
- FURY $0.89
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- FURY 53.60
- INKT 50.15
- Support Level
- FURY $0.70
- INKT $13.88
- Resistance Level
- FURY $0.88
- INKT $15.00
- Average True Range (ATR)
- FURY 0.07
- INKT 0.83
- MACD
- FURY 0.00
- INKT -0.00
- Stochastic Oscillator
- FURY 42.54
- INKT 41.14
About FURY Fury Gold Mines Limited
Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.